Vinita Gupta

About

When Vinita Gupta joined Lupin in 1992, the Mumbai-based company had grown as a top domestic pharma company specialised in TB drugs and antibiotics. But her father and founder of Lupin, D.B Gupta, entrusted her with internationalising the business. By 2001, exports to advanced markets crossed ₹100 crore, and by 2003, Lupin entered the U.S. generic pharmaceuticals market with ANDA approval for cefuroxime axetil tablets (Suprax), which was launched in 2008. Since then Vinita has unleashed a string of acquisitions globally in Japan, Germany, Australia, South Africa, the Philippines, Brazil, Mexico, the U.S. and the Netherlands. By 2010, it became the fifth-largest generic player in the U.S. in terms of prescriptions (IMS Health), and by 2013 Vinita took over as the global CEO. In FY24, Lupin reported ₹20,010 crore in sales, a 20% growth over FY23. Currently the 11th-largest generic pharma company globally, the U.S is Lupin’s largest market, generating 37% of total sales, more than the 34% from India. The company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin employs over 23,000 people across 15 manufacturing and 7 R&D sites globally. “Through targeted initiatives, we support gender equality, work towards empowering our women workforce, and foster an inclusive environment,” says Vinita.